A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
This study has been terminated.
(Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients resulting in poor data.)
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
First received: February 9, 2006
Last updated: August 11, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Estimated Study Completion Date:||March 2019|
|Estimated Primary Completion Date:||March 2018 (Final data collection date for primary outcome measure)|